

## Pharnext and Galapagos successfully achieved their research and development collaboration

**PARIS, France, 8:00 am, September 9, 2019 (CET) – Pharnext SA (FR0011191287 - ALPHA)**, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, today announced the successful completion of its research and development collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a late-stage clinical biotechnology company specialized in the discovery and development of small molecule medicines with novel mechanisms of action.

The collaboration aims to generate a new drug development pipeline in several therapeutic areas for Galapagos, including immunoinflammatory disorders. Namely, the collaboration was focused on the identification of:

- *Additional therapeutic indications for Galapagos' clinical drug candidates,*
- *Novel candidates for combinations with Galapagos' current portfolio of drug candidates, and*
- *New therapeutic targets in indications pre-defined by Galapagos.*

Together, Pharnext and Galapagos have met their objectives.

Leveraging its innovative PLEOTHERAPY™ platform, Pharnext successfully identified additional therapeutic indications for Galapagos' candidate drugs. Combining Galapagos' expertise in holistic pharmaceutical development with Pharnext's cutting-edge approach, several of these new indications were further prioritized for experimental validation studies in animal models, in which Galapagos' candidate drugs demonstrated efficacy.

Pharnext's PLEOTHERAPY™ platform also identified multiple approved drugs to combine with Galapagos' candidate drugs in order to create a more potent effect in these selected indications. Some combinations of Galapagos' candidate drugs with Pharnext's identified drugs have already shown a superior effect in relevant animal models.

Finally, Pharnext's PLEOTHERAPY™ platform identified new targets in therapeutic indications that Galapagos had prioritized initially, supporting Galapagos' research and development activities in these indications.

*“These results reaffirm the robustness of Pharnext's development of combination drugs and validate its application to potentially any therapeutic area. Pharnext's innovative approach bolsters the disease treatment path,”* said **Professor Daniel Cohen, MD, PhD, Co-Founder and Chief Executive Officer of Pharnext**. *“We are proud to collaborate with Galapagos to generate new treatment options for patients.”*

*“We want to thank Pharnext for the rewarding collaboration, which has led to the identification of interesting novel combinations that are now in advanced preclinical testing,”* said **Piet Wigerinck, PhD, Chief Scientific Officer of Galapagos**.

This collaboration aims to expand the market of these novel combinations to new indications. Generating new patents should increase the value of these new compounds.

## About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm based on big genomics data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team. More information at [www.pharnext.com](http://www.pharnext.com)

Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).

## About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at [www.glpg.com](http://www.glpg.com)

## CONTACTS

### Pharnext

Daniel Cohen  
Chief Executive Officer  
[contact@pharnext.com](mailto:contact@pharnext.com)  
+33 (0)1 41 09 22 30

### Financial Communication (France)

Actifin  
Stéphane Ruiz  
[sruiz@actifin.fr](mailto:sruiz@actifin.fr)  
+33 (0)1 56 88 11 15

### Investor Relations (U.S.)

Stern Investor Relations, Inc.  
Jane Urheim  
[jane.urheim@sternir.com](mailto:jane.urheim@sternir.com)  
+1 212 362 1200

### Investor Relations (Europe)

MC Services AG  
Anne Hennecke  
[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)  
+49 211 529252 22

### Media Relations (Europe)

Ulysse Communication  
Bruno Arabian  
[barabian@ulyссе-communication.com](mailto:barabian@ulyссе-communication.com)  
+33 (0)1 81 70 96 30

### Media Relations (U.S.)

RooneyPartners  
Kate L. Barrette  
[kbarrette@rooneyco.com](mailto:kbarrette@rooneyco.com)  
+1 212 223 0561

## Disclaimer

*This press release contains certain forward-looking statements concerning Pharnext and its business. Such forward-looking statements are based on assumptions that Pharnext considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in Pharnext's document de base filed with the AMF on June 2, 2016 under number I.016-0050 as well as in any other periodic report and in any other press release (a copy of which is available on [www.pharnext.com](http://www.pharnext.com)) and to the development of economic conditions, financial markets and the markets in which Pharnext operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Pharnext or not currently considered material by Pharnext. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Pharnext to be materially different from such forward-looking statements. Pharnext disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

*This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Pharnext shares in any country.*